Verrica Pharmaceuticals Inc. said it will seek U.S. approval for its skin treatment VP-102 during the second half of the year after it cleared two late-stage studies.
The Camp-1 and Camp-2 clinical trials evaluated the efficacy and safety of VP-102 against placebo in 528 patients with molluscum contagiosum — a common skin disease that occurs mainly in children. The U.S. Food and Drug Administration has yet to approve a treatment for the disease, which is caused by a poxvirus and affects about 6 million people in the U.S. each year.
VP-102 achieved complete clearance of all treatable lesions in 46% and 54% patients after 84 days of treatment in the Camp-1 and Camp-2 phase 3 studies, respectively. This compares to the 18% and 13% of patients in the placebo groups.
The West Chester, Pa.-based drugmaker said the medicine did not cause any major side effects.